Calumet (CLMT) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Completed conversion from MLP to C-Corp in July 2024, increasing institutional investor interest and liquidity, with over 99% unitholder approval.
Secured a $1.44 billion conditional DOE loan commitment for Montana Renewables' MaxSAF expansion, supporting growth in sustainable aviation fuel (SAF).
Achieved record company-wide production volumes, including record quarterly SAF production over 3,200 barrels per day in September.
Performance Brands segment posted record volume growth, and Specialties business benefited from a multi-year commercial excellence program.
Reported a net loss of $100.6 million for Q3 2024, or $1.18 per share, compared to net income of $99.8 million in Q3 2023.
Financial highlights
Q3 2024 total Adjusted EBITDA was $49.8 million, down from $75.4 million in Q3 2023.
Specialty Products and Solutions Adjusted EBITDA rose to $42.6 million from $38.6 million in Q3 2023, with margins now consistently in the $60–$70 per barrel range.
Performance Brands Adjusted EBITDA increased to $13.6 million from $13.2 million year-over-year, with 19% quarterly and 21% year-to-date volume growth.
Montana Renewables Adjusted EBITDA declined to $12.7 million from $38.2 million in Q3 2023, impacted by commodity headwinds and lower fuel credits.
Q3 2024 sales were $1,100.4 million, down from $1,149.4 million in Q3 2023.
Outlook and guidance
SAF capacity at Montana Renewables expected to reach 150 million gallons annually by 2026, with further modular expansions planned to 300 million gallons.
CapEx outlook for the year remains at $100 million or slightly lower.
Focus remains on deleveraging in the near term, with capital allocation prioritized for debt reduction.
Q4 2024 will reflect the impact of a planned turnaround at Montana Renewables.
The Montana refinery sale-leaseback provides additional liquidity and financial flexibility, allowing continued operations and future repurchase options.
Latest events from Calumet
- Adjusted EBITDA rose 30%, net loss narrowed, and $222M debt was cut amid record specialty output.CLMT
Q4 202527 Feb 2026 - Q2 2024 delivered $66.8M EBITDA, record volumes, and C-Corp conversion amid margin pressure.CLMT
Q2 20241 Feb 2026 - DOE loan enables major SAF expansion, debt reduction, and strategic growth for renewables.CLMT
Status Update10 Jan 2026 - Unitholders to vote on conversion to a corporation, exchanging units for shares and warrants.CLMT
Proxy Filing2 Dec 2025 - C-Corp conversion, DOE loan, and asset sale drive deleveraging and renewables growth.CLMT
Q4 20241 Dec 2025 - Q2 2025 posted a $147.9M loss, but cost cuts and specialty gains drove operational progress.CLMT
Q2 202523 Nov 2025 - Q1 2025 net loss deepened, but EBITDA, liquidity, and SAF expansion advanced.CLMT
Q1 202520 Nov 2025 - Q3 2025 saw record EBITDA, net income, and SAF progress, with cost cuts and deleveraging.CLMT
Q3 202513 Nov 2025